Boston Scientific Corporation announced enrollment completion in its PERSEUS trial.

The trial, designed to evaluate their third-generation TAXUS(R) Element(TM) paclitaxel-eluting coronary stent, has enrolled close to 1,500 patients at 100 U.S. and international centers since July 2007. PERSEUS will compare the TAXUS(R) Element(TM) stent to the prior-generation TAXUS(R) Express2(TM) stent marketed in the United States since 2004, as the company intends to develop additional versions of the platform, including next generations of a bare-metal stent and an everolimus-eluting PROMUS(R) Element(TM) stent system.

The TAXUS PERSEUS clinical program will evaluate the efficacy and safety of the TAXUS(R) Element(TM) stent in two studies: The TAXUS PERSEUS Workhorse will evaluate the safety and efficacy of the TAXUS(R) Element(TM) stent compared to Boston Scientific's first generation drug-eluting stent, the TAXUS(R) Express(TM) Stent while a second parallel study named the TAXUS PERSEUS Small Vessel study will compare the TAXUS(R) Element(TM) stent to a historic control (TAXUS V de novo bare-metal Express(R) coronary stent system).

The Element stent platform features the Boston Scientific’s proprietary platinym chromium alloy, which was designed specifically for stents.

Boston Scientific is currently seeking CE Mark approval in European markets, which is anticipated in 2009.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.

Source: Boston Scientific Corporation